课题基金 / 基金详情

项目摘要

项目成果

MACIEJ S LESNIAK的其他基金

相似基金

相关文献

中文摘要
翻译
发展性研究计划:综述 DRP是脑孢子的重要组成部分,每年为3-4个具有 翻译潜力。资金是灵活的,支持项目的期限为两年或更短时间。这是意料之中的 DRP调查人员将充分发展他们的飞行员,要么取代已经达成的主要项目 结论,或者没有进展。如果没有这样的需要,将鼓励DRP项目调查人员 通过R01机制获得独立资金。DRP将在整个 项目期间;孢子资金将得到机构支持的匹配。 与西北大学合作 在卢里癌症中心的脑瘤研究所,将有一个高度结构化的征集过程, 审查和评价试点项目;将大力鼓励妇女和少数群体调查员申请。 DRP的具体目标是: 目标1.征集、确定和支持被认为具有以下特点的有价值的翻译研究项目 极有可能影响脑肿瘤的诊断和/或治疗和/或预防。 目标2.促进发展项目成熟为全孢子项目或独立资助的项目 项目。 目标3.吸引目前没有从事脑瘤研究的杰出的新的和有经验的研究人员 从事脑瘤研究,特别强调支持妇女和少数族裔调查人员。
英文摘要
DEVELOPMENTAL RESEARCH PROGRAM: SUMMARY The DRP is an essential component of the Brain SPORE, providing yearly support to 3-4 projects that have translational potential. Funding is flexible, supporting projects for a period of two years or less. It is expected that DRP investigators will develop their pilots sufficiently to either replace main projects that have reached conclusion, or are not progressing. If there is no such need, DRP project investigators will be encouraged to secure independent funding, such a through the R01 mechanism. The DRP will be maintained for the entire project period; SPORE funds will be matched by Institutional support. In collaboration with the Northwestern's Brain Tumor Institute at the Lurie Cancer Center, there will be a highly structured process for solicitation, review and evaluation of pilot projects; women and minority investigators will be strongly encouraged to apply. The specific aims of the DRP are: Aim 1. To solicit, identify and support meritorious translational research projects that are considered as having a high probability of impacting the diagnosis and/or treatment and/or prevention of brain tumors. Aim 2. To facilitate developmental project maturation into full SPORE projects or independently funded projects. Aim 3. To attract outstanding new and experienced investigators currently not working on brain tumors to pursue brain tumor research, with a special emphasis on supporting women and minority investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
SPORE for Translational Approaches to Brain Cancer
海外基金